Many people with epilepsy take antiepileptic drug (AED) polytherapy, although supportive evidence for the success of this strategy is sparse. Of 2881 treated patients registered in our database, 1617 (56%) have been seizure-free for at least the previous year, with 21% taking more than one AED (287 on two, 86%; 42 on three, 13%; 3 on four, 1%). There were 40 effective duotherapies and 28 triple therapies. Treatment with two or three but not four AEDs may be a useful therapeutic option for patients not responding to monotherapy. Further explorations of the best regimens for individual seizure types and epilepsy syndromes is required.
INTRODUCTION
Antiepileptic drugs (AEDs) are the mainstay of treatment for people with epilepsy. Around 60% of patients with newly diagnosed epilepsy will be controlled with the first or second AED 1 , often at modest or moderate dosing 2 . Once two drugs have failed, however, the chance of seizure freedom with further monotherapy options is very low 3 . This suggests that a substantial number of patients will receive treatment with two or more AEDs. The literature has tended to focus on the disadvantages rather than the successes of polytherapy in epileptic patients 4 .
There are surprisingly few data to guide clinicians on strategies for combining AEDs despite the introduction of nine new agents over the last decade. With advances in the understanding of the pathophysiology of seizure initiation and propagation 5 and the modes of AED action 6 , the scope for rational polytherapy is increasing 7 . There is an emerging consensus that combining AEDs based on mechanism of action may enhance effectiveness 8, 9 . This report documents the different polytherapy regimens taken by seizure-free patients attending the Epilepsy Unit at the Western Infirmary in Glasgow, Scotland.
PATIENTS
The population consisted of consecutive patients referred to the Epilepsy Unit from January 1, 1984. At the initial appointment, demographic and clinical information were obtained from the patient and any witnesses to the seizures using a structured questionnaire. These data together with results of subsequent investigations were entered into a database. Classification of seizure type and/or epilepsy syndrome was carried out according to the guidelines of the International League Against Epilepsy 10 .
AED choice depended on seizure type or epilepsy syndrome taking into consideration the mechanism of action and the side-effect and interaction profiles 11 . Patients were seen every 4-6 weeks, or sooner if indicated. At each visit response to treatment and any adverse events were recorded. Compliance was monitored by measuring circulating AED levels. Doses were adjusted according to clinical response. The original drug was substituted if seizure control was not obtained despite optimal dosing or if the patient complained of intolerable side-effects. A combination of drugs was used in patients in whom seizure freedom proved elusive despite treatment with one, two or sometimes three monotherapy options. When necessary a sequence of combinations was tried with the aim of achieving complete seizure control. For patients uncontrolled with two AEDs, a third and sometimes a fourth AED was added. Seizure freedom was defined as absence of seizures or auras for at least the previous year on unchanged medication.
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RESULTS
At the time of analysis (January-March 2000), 2881 patients were receiving AED treatment. Of these, 1617 (56%) had been seizure-free for at least the previous year, with 1285 (79%) being controlled with a single AED. The remaining 332 (21%) patients (166 of both sexes, median 49 years, age range 14-85 years) took more than one AED. The majority of these were controlled with two (n = 287, 86%), or three (n = 42, 13%) AEDs. Just three seizure-free patients (1%) were taking four drugs. Overall, 192 (58%) patients taking polytherapy had partial and/or secondary generalized seizures. The remaining 140 (42%) patients reported primary generalized seizures (120 tonic-clonic, 15 myoclonic, five absence). Thirty-nine (12%) patients also had learning disability. There were 40 effective duotherapy regimens, the commonest being sodium valproate with lamotrigine and phenobarbital with phenytoin (Table 1) . Mean doses and ranges for the ten most successful duotherapies are listed in Table 2 . Twenty-eight triple therapy schedules resulted in seizure freedom, most frequently sodium valproate with lamotrigine and topiramate (Table 3) . 6 . The commonest efficacious duotherapy in this study was sodium valproate with lamotrigine, which has been reported to have greater efficacy for partial and tonicclonic seizures than phenytoin or carbamazepine with lamotrigine 12 . Evidence is accumulating in support of synergism with these two drugs which may have a pharmacodynamic as well as a pharmacokinetic basis 13 . The number of seizure-free patients talking phenobarbital with phenytoin reflects previous experience 14, 15 . Doses employed in the various duotherapy regimens varied widely suggesting substantial variation in response.
Treating patients with refractory epilepsy provides a major therapeutic challenge. This survey supports our previous observations in patients with symptomatic and cryptogenic epilepsy 16 that combining two or at most three AEDs may be a useful therapeutic option when monotherapy fails. The wide range of effective combinations suggests substantial pathophysiological diversity in the causation of difficult-to-control epilepsy. Further exploration of the best regimens for individual seizure types and epilepsy syndromes is required. We believe that combination therapy using drugs with potentially complementary modes of action forms an essential component of a staged approach to the management of difficult-to-control epilepsy 17 .
